DeBogy Molecular

DeBogy Molecular is a private U.S. biotechnology company developing a proprietary antimicrobial surface-modification platform for medical applications, particularly implantable devices. Its technology is designed to permanently alter material surfaces so they kill bacterial, viral, and fungal cells on contact without relying on antibiotics, toxic chemicals, or conventional coatings. The company appears to be focused first on orthopedic and other medical implants, where bacterial biofilm and implant-related infections are major clinical problems. DeBogy has reported preclinical in vivo data showing substantial reductions in bacterial biofilm on treated titanium implants and has stated plans to pursue FDA approval with medical device industry partners. Beyond healthcare, the platform is described as applicable across additional materials and industrial sectors.